Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.
CAT No: R1721
CAS No:2023788-19-2
Synonyms/Alias:Tirzepatide;2023788-19-2;C225H348N48O68;DA-78491;
Tirzepatide is a synthetic peptide designed as a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Structurally, it is a 39-amino acid peptide that incorporates both GIP and GLP-1 receptor agonism within a single molecular framework, making it a valuable tool for investigating incretin biology and metabolic regulation. Its unique mechanism of action, engaging two distinct incretin pathways, has positioned it as a compound of significant interest in metabolic research, particularly in studies focused on glucose homeostasis, insulin sensitivity, and energy balance. The ability to modulate both GIP and GLP-1 signaling cascades provides researchers with a sophisticated approach to dissecting the interplay between gut hormones and systemic metabolic processes.
Metabolic pathway elucidation: As a dual incretin receptor agonist, tirzepatide is widely utilized in preclinical studies to unravel the complex signaling events underlying metabolic homeostasis. Researchers employ it to probe the physiological roles of GIP and GLP-1 receptors in glucose-stimulated insulin secretion, glucagon regulation, and appetite control. Through in vitro and in vivo experiments, the compound aids in mapping downstream signaling networks, receptor cross-talk, and the integrated responses of pancreatic islets, adipose tissue, and the central nervous system to incretin stimulation.
Obesity and energy balance research: In the context of obesity and energy regulation, tirzepatide serves as a model compound for examining the hormonal control of satiety, food intake, and body weight. Its dual agonist activity allows for the assessment of additive or synergistic effects on appetite suppression and energy expenditure, providing insights into the neuroendocrine mechanisms that govern caloric intake and fat storage. Studies utilizing this peptide have contributed to a deeper understanding of how gut-derived hormones influence hypothalamic pathways and peripheral metabolic outcomes.
Insulin sensitivity and glucose tolerance studies: The compound is frequently applied in experimental models to evaluate its effects on insulin sensitivity, glucose uptake, and overall glycemic control. By activating both GIP and GLP-1 receptors, it enables detailed investigation into the enhancement of insulin action in peripheral tissues, such as skeletal muscle and adipose tissue, as well as the modulation of hepatic glucose production. These studies are instrumental in characterizing the molecular determinants of insulin resistance and identifying new targets for metabolic intervention.
Peptide engineering and structure-activity relationship (SAR) analysis: Tirzepatide's unique chimeric structure makes it an instructive template for peptide engineering and SAR investigations. Researchers leverage its sequence and receptor-binding properties to design and optimize novel incretin-based peptides with tailored pharmacological profiles. Comparative studies involving analogs and modified peptides provide valuable data on receptor selectivity, potency, and metabolic stability, advancing the development of next-generation research tools in the peptide therapeutics field.
Pharmacodynamic and pharmacokinetic profiling: The dual-receptor activity and extended half-life of tirzepatide present opportunities for comprehensive pharmacodynamic and pharmacokinetic analyses in animal models and in vitro systems. These studies focus on absorption, distribution, metabolism, and excretion patterns, as well as receptor occupancy and downstream biomarker responses. Such profiling supports the optimization of peptide-based compounds for research use, informing experimental design and the interpretation of metabolic outcomes in a controlled laboratory setting.
1. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
2. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
3. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More